- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 25.03. | Resolutions of the Annual General Meeting 2026 of Curasight A/S | 2 | Cision News | ||
| 10.03. | CURASIGHT: Notice of Annual General Meeting 2026 | 1 | Cision News | ||
| 06.03. | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | 1 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 287 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 09.02. | CURASIGHT: Major Shareholding Notification | 4 | Cision News | ||
| 12.01. | Curasight reports early positive data from brain cancer treatment trial | 3 | Investing.com | ||
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 453 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 353 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 29.12.25 | Curasight A/S resolves to issue a convertible loan note | 2 | Cision News | ||
| 29.12.25 | CURASIGHT: Resolutions of the Extraordinary General Meeting December 2025 | 4 | Cision News | ||
| 18.12.25 | Curasight: Erster Patient in Phase-1-Studie zu Hirntumor-Therapie behandelt | 3 | Investing.com Deutsch | ||
| 18.12.25 | Curasight doses first patient in phase 1 brain cancer treatment trial | 1 | Investing.com | ||
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 586 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 14.12.25 | CURASIGHT: Notice of Extraordinary General Meeting | 1 | Cision News | ||
| 12.12.25 | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility | 3 | Cision News | ||
| 12.12.25 | Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility | 1 | Cision News | ||
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 891 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 28.11.25 | Curasight to present at HC Andersen Capital | 1 | Cision News | ||
| 27.11.25 | CURASIGHT: Interim report Q3 2025 | 2 | Cision News |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 34,160 | +0,09 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,650 | -0,07 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,620 | 0,00 % | Tango Therapeutics Shares Fall 17% | ||
| KYMERA THERAPEUTICS | 80,61 | 0,00 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| SUMMIT THERAPEUTICS | 17,475 | +0,03 % | Bernstein downgrades Summit Therapeutics stock rating on trial concerns | ||
| PRAXIS PRECISION MEDICINES | 350,56 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,110 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| NUVALENT | 101,24 | 0,00 % | Bernstein startet Coverage für Nuvalent mit "Outperform"-Rating und hohem Kursziel | ||
| ERASCA | 11,600 | -0,04 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,570 | -0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,540 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| ALUMIS | 22,170 | 0,00 % | This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday | ||
| IMMIX BIOPHARMA | 8,650 | -0,23 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,660 | -0,04 % | Beam Therapeutics presents AATD gene therapy trial data at ATS |
Das Unternehmen CURASIGHT A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,26 % bei einem Aktienkurs von 1,955 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.